INTRODUCTION
The clinical development of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib has firmly established non-small-cell lung cancer (NSCLC) harboring ALK gene rearrangements as a distinct molecular subset of lung cancer. [1] [2] [3] [4] [5] Crizotinib has demonstrated superior progression-free survival benefit compared with chemotherapy in the firstor second-line setting for ALK-rearranged NSCLC, with a median progression-free survival (PFS) of 10.9 months and 7.7 months, respectively. 4, 5 However, almost all patients invariably experience progression on crizotinib, and approximately 40% of the patients with ALK-rearranged NSCLC develop CNS metastases as an initial site of progression. 6 In addition, approximately 60% of patients with ALK-rearranged NSCLC who enrolled onto a subsequent ALK inhibitor study after experiencing progression while receiving crizotinib had baseline CNS metastases, compared with only 26% of the treatment-naïve patients with advanced ALKrearranged NSCLC who enrolled onto the frontline PROFILE 1014 trial. 5, 7 Alectinib (CH5424602; Chugai/F. HoffmannLa Roche, Basel, Switzerland) is an oral, smallmolecule, ATP-competitive, tyrosine kinase inhibitor of ALK. 8 In enzymatic assays, alectinib is approximately five times more potent than crizotinib against ALK and can inhibit most of the clinically observed acquired ALK resistance mutations to crizotinib. 9, 10 In contrast to crizotinib, alectinib does not inhibit the kinase activity of MET or ROS1; however, it does inhibit RET with similar potency to ALK (50% inhibitory concentration [IC 50 ], 4.8 nmol/L and 1.9 nmol/L, respectively). 11 In xenograft models of ALKrearranged NSCLC, alectinib showed marked antitumor activity against both crizotinib-sensitive and crizotinib-resistant tumors. 9, 10 In addition, alectinib demonstrated excellent CNS tissue penetration and tumor shrinkage in a murine brain metastasis xenograft model, and it demonstrated comparable free alectinib concentrations in plasma and cerebral spinal fluid (CSF), which supports the ability of alectinib to penetrate into the CNS. 12 An ongoing North American study of alectinib in patients with ALK-rearranged NSCLC who had experienced progression while receiving crizotinib established the recommended phase II dose (RP2D) of alectinib as 600 mg twice daily. 13 We conducted this global, single-arm, phase II study to determine the safety, efficacy, and pharmacokinetics (PK) of alectinib in patients with advanced ALK-rearranged NSCLC who had experienced progression while receiving crizotinib.
PATIENTS AND METHODS
Patients were eligible for inclusion if they had locally advanced or metastatic NSCLC harboring an ALK rearrangement and had experienced progression while receiving crizotinib, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Patients could be chemotherapy naïve or could have received prior platinum-based chemotherapy.
Study Oversight
This study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonization. The protocol was approved by the local institutional review boards/ethics committees at each participating site. Written informed consent was obtained from all patients before screening.
Study Design
The primary objectives were to determine the objective response rate (ORR) by independent review committee (IRC) in all evaluable patients and in patients previously treated with chemotherapy. Key secondary objectives were to characterize the PK profile, the safety and tolerability profile, PFS, and overall survival and to evaluate the efficacy of alectinib in the CNS.
Key eligibility criteria included histologically confirmed, advanced NSCLC with an ALK rearrangement previously assessed by a US Food and Drug Administration-approved test (Abbott Vysis LSI breakapart fluorescence in situ hybridization [FISH] ; retesting not required), disease progression while receiving crizotinib as per RECIST 1.1, age 18 or older, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less, adequate organ function, and measurable disease according to RECIST 1.1. Patients with stable ($ 2 weeks) treated brain and/or leptomeningeal metastases or asymptomatic ($ 2 weeks) untreated brain and/or leptomeningeal metastases were allowed to enroll. A minimum wash-out period of 7 days was required between the last dose of crizotinib and the first dose of alectinib. Full inclusion and exclusion criteria are provided in the Data Supplement.
Study treatment was alectinib 600 mg twice daily within 30 minutes after eating. Patients continued treatment with alectinib until disease progression, unacceptable toxicity, or withdrawal of consent occurred.
Treatment beyond disease progression was permitted if the treating physician considered it beneficial in consultation with the sponsor.
The first patient was enrolled on June 20, 2013, and the last patient was enrolled on April 23, 2014. The primary data cutoff was performed on August 18, 2014. An updated efficacy analysis was performed with a data cutoff of January 8, 2015.
Study Assessments
Adverse events (AEs) were graded according to the National Cancer Institute Common Terminology Criteria for AEs, version 4.0. Intensive and sparse blood samples for PK assessments were obtained.
All patients underwent tumor imaging at baseline, including computed tomography of the chest and abdomen as well as brain imaging (computed tomography or magnetic resonance imaging). Restaging scans were obtained at 8-week intervals during treatment. Brain imaging was also performed at 8-week intervals for patients with baseline brain metastases. In addition to a review of radiographs by the local investigator, a central IRC was established to perform independent radiologic review of all scans according to RECIST 1.1.
14 A central IRC was also used to assess all CNS end points.
Statistical Analysis
This was a single-arm, global, phase II study. To ensure sufficient power in the subgroup of patients who had been treated with prior chemotherapy, a sample size of 85 was chosen, such that the lower limit of the two-sided 95% CI (using an exact Clopper-Pearson CI) around the point estimate of the ORR allowed for identification of a clinically relevant response, to reject the null hypothesis that ORR equals 35%. Therefore, a total enrollment of 130 patients was planned, with a maximum of 45 chemotherapy-naïve patients, to achieve 93% power on the basis of an exact test for a single proportion, to detect a 15% increase in ORR from 35% to 50% at the 5% two-sided significance level. Hierarchical testing was used, and the primary analysis was tested in the all-patients group; if significant, a subsequent test was carried out in the subgroup of patients who had prior exposure to cytotoxic chemotherapy.
The response evaluable (RE) population comprised patients with measurable disease at baseline who had a baseline tumor assessment and who had received at least one dose of alectinib at the RP2D of 600 mg twice daily. Safety data are summarized for all patients who received at least one dose of alectinib. ORR was defined as the proportion of patients achieving a best response of complete response (CR) or partial response (PR) in the RE population. PFS was calculated from the date of first administration of alectinib until disease progression or death as a result of any cause occurred. Kaplan-Meier analyses of time-to-event data were used to estimate median event times, and the Brookmeyer-Crowley method was used to calculate two-sided 95% CIs. A competing risks model, which had a hazardbased approach that included successive nested competing-risks experiments, was used to account for the competing risks inherent in time to progression in the CNS. The probability of the first event being a CNS progression, non-CNS progression, or death was estimated by using cumulative incidence functions. All analyses were performed with the use of SAS statistical software, version 9.2 (SAS Institute, Cary, NC).
RESULTS

Patients
From June 2013 to April 2014, 138 patients were treated at 56 centers in 16 countries and were evaluable for safety, PFS, and overall survival. Sixteen patients did not have RECIST-measurable target lesions when assessed by the IRC; therefore, 122 patients were considered RE by IRC (Data Supplement). The majority of patients (61%) had CNS metastasis at study entry, of whom 42% (35 of 84) had measurable CNS metastases and 73% (61 of 84) had received prior brain radiation. Of the 61 patients who received brain radiation, 64% completed radiation more than 6 months before starting alectinib, 12% completed brain radiation less than 6 months but 4 weeks or more before starting alectinib, and 8% of the patients completed radiation less than 4 weeks before starting alectinib. Furthermore, 80% of the patients had received at least one previous line of chemotherapy in addition to crizotinib (Table 1 and Data Supplement). The median duration of treatment on crizotinib for all patients was 364 days (12 months) as reported by the investigators (25th percentile, 257 days; 75th percentile, 609 days; Data Supplement). Investigator-assessed best response to crizotinib was PR (54%), stable disease (22%), progressive disease (20%), and unavailable (4%) among all enrolled patients. The median time from last dose of crizotinib to first dose of alectinib for all patients was 15 days (range, 7 to 676 days). The median follow-up time for all patients was 30 weeks (range, 2 to 53 weeks) at the primary data cutoff and was 47 weeks (range, 2 to 73 weeks) at the latest efficacy data cutoff.
Efficacy
Tumor response. Among the RE population by IRC (n = 122), the coprimary end point of ORR was met; 49% (95% CI, 40% to 58%) at the primary cutoff, and 50% (95% CI, 41% to 59%), at the updated cut-off; and the disease control rate (DCR) was 79% (95% CI, 70% to 86%; Fig 1 and Data Supplement) . Among the 96 patients in the IRC RE population who had received prior chemotherapy (coprimary end point), the ORR was 44% (95% CI, 34% to 54%) at the primary cutoff, which was not statistically significant but was still clinically meaningful, and the ORR was 45% (95% CI, 35% to 55%) at the updated cutoff; the DCR was 77% (95% CI, 67% to 85%; Data Supplement). Due to the hierarchical order of testing, the overall study is considered positive, because the first coprimary end point was met. For the 26 chemotherapy-naïve patients who belonged to the IRC RE population, the ORR was 69% (95% CI, 48% to 86%; Data Supplement). At the time of the latest data cutoff, 41 (67%) of 61 responses were ongoing. ORR data obtained by investigator were consistent with the IRC data (Data Supplement).
Duration of response and progression-free survival. Among the 61 patients with PR, the median duration of response (DOR) by IRC was 11.2 months (95% CI, 9.6 months to not reached), and only 20 patients (33%) had an event (progressive disease, n = 16; death, n = 4; Fig 1B) . Overall, median PFS was 8.9 months (95% CI, 5.6 to 11.3 months), and 80 (58%) of the 138 patients treated had a PFS event (Fig 1C) at time of analysis. For the 28 chemotherapy-naïve patients, the median PFS was 13.0 months (95% CI, 5.5 months to not reached). At the time of the primary data cutoff, 24 of the 138 patients had died, and the 6-month eventfree rate was 87% (95% CI, 81% to 92%; Data Supplement).
CNS efficacy. Of the 84 patients with baseline CNS metastases at study entry, 61 (73%) had previous brain radiation. The majority of these 61 patients (64%) received CNS radiation more than 6 months before starting alectinib treatment (Data Supplement). Of the 35 patients with baseline measurable CNS lesions, the CNS ORR was 57% (95% CI, 39% to 74%) and included seven patients who had a CNS CR (Fig 2A and Data Supplement) . Among the 84 patients with baseline CNS metastases, 23 patients (27%) achieved a CNS CR, and the overall CNS DCR was 83% (95% CI, 74% to 91%; Data Supplement). The CNS DOR for these 84 patients was 10.3 months (95% CI, 7.6 to 11.2 months; Fig 2B) . Among the 23 patients who had no prior brain radiation, 10 patients achieved a CNS CR (43%). At 12 months, 33 patients (cumulative incidence rate, 24.8%) had a CNS progression, 43 patients (cumulative incidence rate, 33.2%) had a non-CNS progression, and nine patients (cumulative incidence rate, 6.6%) died without a documented progression. The incidence of non-CNS progressions increased earlier than the incidence of CNS progressions, whereas the cumulative incidence of deaths showed a slow increase over time compared with other event types (Fig 2C) .
Safety. At the time of the primary data cutoff, the median duration of treatment was 27.1 weeks (range, 2.4 to 53.0 weeks). The most common AEs reported regardless of cause were constipation The cumulative CNS progression rate is shown in blue. The cumulative non-CNS progression rate is shown in gold. The cumulative incidence of death is shown in gray. BOR, best overall response; CR, complete response; NE, not estimable; PD, progressive disease; PR, partial response; SD, stable disease.
(33%), fatigue (26%), and peripheral edema (25%; Table 2 ). The most common treatment-related AEs were myalgia (17%), constipation (15%), fatigue (14%), and asthenia (11%). Incidence of grades 3 to 4 AEs was low in the study (Table 2) .
A total of 29 (21%) of 138 patients had a dose reduction and/ or interruption, mainly because of laboratory abnormalities, and the mean duration of treatment interruptions was 10 days. The mean dose intensity was 97%, which indicated that most patients were able to sustain therapeutic levels of alectinib throughout the study. In 11 (8%) of 138 patients, alectinib was permanently discontinued because of an AE. Four patients (3%) died as a result of AEs (intestinal perforation, dyspnea, pulmonary embolism, and hemorrhage). Only the intestinal perforation was considered possibly related to study treatment.
Pharmacokinetics. After multiple oral doses of alectinib 600 mg twice daily under fed conditions, the geometric mean peak-to-trough ratio of alectinib on day 21 was 1.23, which indicated an overall flat PK profile for alectinib and supported a sustained alectinib exposure throughout the dosing interval (Data Supplement). Exploratory evaluation of alectinib plasma levels at steady state between a limited number of patients (white, n = 6; Asian, n = 20) showed a large overlap in exposure, which indicated that alectinib exposures are not markedly different between white and Asian populations at 600 mg twice daily (Data Supplement).
DISCUSSION
The development of resistance to crizotinib is a major barrier to the successful long-term treatment of patients with ALK-rearranged NSCLC. Progression with crizotinib can be due to acquired resistance mutations in ALK, activation of other signaling bypass pathways, and, in approximately half of the patients treated with crizotinib, development and/or progression of brain metastases. 15, 16 Crizotinib has demonstrated potential clinical activity in the CNS, but it remains to be determined whether the high frequency of CNS progression among patients on crizotinib is caused by pharmacodynamic failure of crizotinib or natural history of ALK-rearranged NSCLC, which could involve similar biologic mechanisms of resistance. [17] [18] [19] Therefore, novel ALK inhibitors should not only be more potent than crizotinib and able to inhibit the clinically relevant acquired resistance mutations in ALK but also confer sustained clinical activity in the CNS.
Oral alectinib 600 mg twice daily demonstrated potent clinical activity in patients with advanced, ALK-rearranged NSCLC who had experienced progression while receiving crizotinib, most of whom had also received at least one prior line of platinum-based chemotherapy. Alectinib also resulted in shrinkage of CNS metastases, with a CNS ORR of 57% in patients who had measurable CNS metastases and a CNS CR rate of 27% among all (8) 1 (1) 1 (1) 1 (1) 14 (10) ALT elevation 6 (4) 5 (4) 1 (1) 1 (1) 13 (9) Peripheral edema 10 (7) 2 (1) 1 ( patients who had CNS metastases; sustained durable response (median, 10.3 months) was prospectively assessed by an IRC. The observed CNS clinical activity of alectinib is consistent with the preclinical data of high CNS tissue penetration of alectinib and the comparable CSF-to-unbound plasma ratio of alectinib observed in another clinical study. 12,13 Moreover, it is consistent with the observed CNS ORR of 52% and the CNS CR rate of 29% observed in the dose-finding portion of the US phase I/II study (NP28761) of alectinib. 13 Additionally, alectinib has been reported to be effective against leptomeningeal carcinomatosis in patients with ALK-positive NSCLC who had experienced progression while receiving crizotinib alone 13, 20 or while receiving both crizotinib and ceritinib. 21 Importantly, the cumulative incidence rate of CNS progression was lower than the cumulative incidence rate of non-CNS progression for all patients in this trial, which seems to suggest that alectinib can prevent or delay the emergence of CNS metastases. However, one caveat to this analysis is that brain imaging was not performed at a regular interval among patients without baseline CNS metastasis. Therefore, the true incidence of CNS progression could have been underestimated. Ceritinib, another novel ALK inhibitor, was recently approved in the United States and Europe for patients with ALK-rearranged NSCLC who have experienced progression while receiving crizotinib. 7, 22 In a small number of patients with measurable brain metastases (N = 24), ceritinib achieved a CNS ORR of 29%, 23 and 42% of patients with crizotinib-resistant ALK-rearranged NSCLC who experienced progression while receiving ceritinib had CNS as the only site of relapse. 7 The National Cancer Institute currently is planning a master protocol to address the optimal sequential use of various ALK inhibitors, which should provide additional insight to guide treatment decisions.
Alectinib has also demonstrated impressive ORR (94%) and PFS (median not yet reached, but estimated at . 29 months) in Japanese patients with ALK-positive NSCLC who were ALK inhibitor naïve. 24 In the dose-finding portion of the US phase I/II alectinib study, steady state exposures of alectinib achieved at 600 mg twice daily in white patients met or exceeded the exposures of alectinib achieved with 300 mg orally twice daily in Japanese patients. 25, 26 However, in this study, we did not detect marked differences in alectinib exposure at 600 mg twice daily among a small subgroup of white and Asian patients who underwent intensive pharmacokinetic analysis (Data Supplement).
Overall, the efficacy and safety profile of alectinib compare favorably with available data from other ALK inhibitors. 4, 5, 7, 19, 22, 27 Common AEs were primarily myalgia, fatigue, and gastrointestinal events, which were generally of grade 1 or 2. Myalgia usually has an early onset and generally resolves within 4 weeks of starting alectinib. Less than one quarter of patients required dose modification, and no grade 3 to 4 AE occurred in more than 5% of patients treated with alectinib. Of note because the median time from the last dose of crizotinib to the start of alectinib was only 15 days, 14% of the patients had peripheral edema, which is a known adverse effect of crizotinib, as a concurrent medical condition before they started taking alectinib. This may explain the higher overall rate of peripheral edema (25%) as an AE compared with the treatmentrelated incidence of 9%, which is more consistent with the percentage of treatment-related peripheral edema reported in another alectinib study. 13 The clinically meaningful ORR and DOR in patients with crizotinib-resistant disease and the sustained CNS response reported from this study, as well as the good tolerability profile, support the additional development of this promising new ALK inhibitor. Alectinib is currently being investigated versus crizotinib in treatment-naïve patients with advanced NSCLC and ALK rearrangement in a global randomized trial with PFS as the primary end point (NCT02075840). This trial will also prospectively examine performance of brain imaging on all enrolled patients at regular fixed-time intervals, regardless of the presence of brain metastases at baseline, and should provide additional evidence about whether alectinib, compared with crizotinib, will delay and/or prevent the emergence of CNS metastases.
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